Cargando…

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression

Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ). Upregulation of A disintegrin and metalloproteinases (ADAMs) is correlated to malignancy; however, whether ADAMs modulate TMZ sensitivity in GBM cells remains unclear. To explore the role of ADAMs in TMZ resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jen-Tsung, Lee, I-Neng, Huang, Cheng, Huang, Hsiu-Chen, Wu, Yu-Ping, Chong, Zhi-Yong, Chen, Jui-Chieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178422/ https://www.ncbi.nlm.nih.gov/pubmed/37175410 http://dx.doi.org/10.3390/ijms24097703

Ejemplares similares

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells
por: Chen, Jui-Chieh, et al.
Publicado: (2019)

MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma
por: Wang, Xingqiang, et al.
Publicado: (2017)

MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells
por: LU, YONG, et al.
Publicado: (2012)

miR-145 Alleviates Smooth Muscle Cell Phenotype Transition via ADAM17-Mediated ACE2 Shedding
por: Wen, Juan, et al.
Publicado: (2023)

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells
por: Cheng, Quan, et al.
Publicado: (2017)

Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets
por: Chien, Chia-Hung, et al.
Publicado: (2019)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
por: Siney, Elodie J., et al.
Publicado: (2016)

MiR-145 inhibits EGF-induced epithelial-to-mesenchymal transition via targeting Smad2 in human glioblastoma
por: Chen, Weijie, et al.
Publicado: (2019)

Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation
por: Tsai, Yu-Ting, et al.
Publicado: (2022)

Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines
por: Koo, Sunwoo, et al.
Publicado: (2012)

NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma
por: Speranza, Maria Carmela, et al.
Publicado: (2012)

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma
por: Khan, Muhammad Babar, et al.
Publicado: (2021)

Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study
por: Mohamed, Doaa I., et al.
Publicado: (2021)

ADAM 17 endopeptidase
Publicado: (2009)

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
por: Areeb, Zammam, et al.
Publicado: (2020)

Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p
por: Yin, Jianxing, et al.
Publicado: (2021)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
por: Wu, Henggang, et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression
por: Gao, Yong-tao, et al.
Publicado: (2016)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

ADAM10 and ADAM17: New Players in Trastuzumab Resistance
por: Duffy, Michael J., et al.
Publicado: (2014)

ADAM10 and ADAM17—Novel Players in Retinoblastoma Carcinogenesis
por: Van Meenen, Dario, et al.
Publicado: (2022)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
por: Feng, Shao-Wei, et al.
Publicado: (2022)

FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma
por: Zhang, Chunli, et al.
Publicado: (2018)

Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
por: Shinsato, Yoshinari, et al.
Publicado: (2013)

MicroRNA Expression Profile Reveals miR-17-92 and miR-143-145 Cluster in Synchronous Colorectal Cancer
por: Meng, Wen-Jian, et al.
Publicado: (2015)

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
por: Hsu, Justin Bo-Kai, et al.
Publicado: (2021)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas
por: Haemmig, S, et al.
Publicado: (2014)

Independent and combined effects of environmental factors and miR-126, miR-143, and miR-145 on the risk of coronary heart disease
por: Lin, Da–Cen, et al.
Publicado: (2017)

Role of ADAM10 and ADAM17 in Regulating CD137 Function
por: Seidel, Jana, et al.
Publicado: (2021)

Differentially expressed miR-127, miR-150, and miR-145 in serum extracellular vesicles are novel diagnostic biomarkers of unstable angina
por: Qu, Yuan, et al.
Publicado: (2023)

miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase
por: Chen, Huiyuan, et al.
Publicado: (2015)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8q02spnb8m7us46cgu0c3haebh